MAPT and Cognitive impairment: In APPswe AD mice, 16-week oral administration of 30 mg/kg/day C3G ameliorated cognitive deficits and AD pathology by facilitating Aβ clearance, quenching neuroinflammation, augmenting endogenous antioxidants, and attenuating pathogenic tau phosphorylation [27].